Clinical trial · Interventional
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer
NCT02862587CI-TRIAL-00023755unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objectives: To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Chemotherapy | — | UNRESOLVED | — |
| Precision Cells | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| precision cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Precision Cells
- description
- precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods.
- interventionNames
- Drug: Chemotherapy
- Biological: precision cells
- type
- ACTIVE_COMPARATOR
- label
- Chemotherapy
- description
- Once a week with a total of six times before 60 days prior to the start of drawing blood.
- interventionNames
- Drug: Chemotherapy
Primary outcomes (2)
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18\~65 years old, male or female; * Life expectancy≥6 months; * ECOG score: 0-3; * Advanced Malignancies (lung cancer) were diagnosed by pathological or clinical physicians; * Enough venous channel, no other contraindications to the separation and collection of white blood cells; * Laboratory examination: white blood cell≥3 x 10\*9/L, blood platelet count≥60 x 10\*/L,hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level; * Signed informed consent; * Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion. Exclusion Criteria: * Expected Overall survival \< 6 months; * Patients with uncontrolled hypertension (\>160/95mmHg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (\> Class II, NYHA), or myocardial infarction within 6 months; * Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc; * Other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month; * Unable or unwilling to provide informed consent, or fail to comply with the test requirements.
References
Publications (0)
Data not yet available
No reference posted for this study.